cardiology careers collections past issues search home
     

J Am Coll Cardiol, 2000; 35:246-253
© 2000 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shinagawa, K.
Right arrow Articles by Ogawa, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shinagawa, K.
Right arrow Articles by Ogawa, S.

EXPERIMENTAL STUDIES

Determination of refractory periods and conduction velocity during atrial fibrillation using atrial capture in dogs

Direct assessment of the wavelength and its modulation by a sodium channel blocker, pilsicainide

Kaori Shinagawa, MDa, Hideo Mitamura, MDa, Akiko Takeshita, MDa, Toshiaki Sato, MDa, Hideaki Kanki, MDa, Seiji Takatsuki, MDa and Satoshi Ogawa, MDa

a Cardiopulmonary Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

Manuscript received January 15, 1999; revised manuscript received August 11, 1999, accepted September 10, 1999.

Reprint requests and correspondence: Dr. Hideo Mitamura, Cardiopulmonary Division, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
mitamura{at}med.keio.ac.jp

OBJECTIVES

The purposes of this study were to measure the atrial refractory period and the conduction velocity (CV) during atrial fibrillation (AF) and to explore the antiarrhythmic mechanism of a sodium channel blocker, pilsicainide, during AF.

BACKGROUND

Sodium channel blockers not only decrease the CV, but also prolong the atrial refractory period, particularly during rapid excitation. Because these effects on the wavelength are counteractive and rate dependent, it is critical to measure these parameters during AF.

METHODS

In eight dogs, after AF was induced under vagal stimulation, a single extra-stimulus was repeatedly introduced from the left atrium and its capture was statistically determined for each coupling interval. The local CV was also measured during constant capture of the fibrillating atrium by rapid pacing. The same procedure was repeated after pilsicainide administration.

RESULTS

Pilsicainide significantly increased the mode of AF intervals from 81 ± 10 to 107 ± 16 ms (p < 0.01). While the CV was decreased from 0.9 ± 0.1 to 0.7 ± 0.1 m/s (p < 0.02), the effective refractory period during AF was increased from 69 ± 11 ms to 99 ± 17 ms (p < 0.01). As a result, the wavelength was significantly increased by pilsicainide from 6.6 ± 0.9 to 7.6 ± 1.2 cm (p < 0.05).

CONCLUSIONS

During AF, whereas the sodium channel blocker pilsicainide decreases CV, it lengthens the wavelength by increasing the refractory period, an action that is likely to contribute to the drug’s ability to terminate the arrhythmia. The direct measurement of refractoriness and CV during AF may provide new insights into the determinations of the arrhythmia and antiarrhythmic drug action.

Abbreviations and Acronyms
  AF = atrial fibrillation
  Avg FF = average of 100 atrial activation (FF) intervals
  CI = coupling interval
  CV = conduction velocity
  ERPAF = effective refractory period during atrial fibrillation
  FRPAF = functional refractory period during atrial fibrillation
  Mode FF = mode of 100 FF intervals




This article has been cited by other articles:


Home page
EuropaceHome page
V. Jacquemet, N. Virag, and L. Kappenberger
Wavelength and vulnerability to atrial fibrillation: Insights from a computer model of human atria
Europace, January 1, 2005; 7(s2): S83 - S92.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. Reisinger, E. Gatterer, W. Lang, T. Vanicek, G. Eisserer, T. Bachleitner, C. Niemeth, F. Aicher, W. Grander, G. Heinze, et al.
Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset
Eur. Heart J., August 1, 2004; 25(15): 1318 - 1324.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Kawase, T. Ikeda, K. Nakazawa, T. Ashihara, T. Namba, T. Kubota, K. Sugi, and H. Hirai
Widening of the Excitable Gap and Enlargement of the Core of Reentry During Atrial Fibrillation With a Pure Sodium Channel Blocker in Canine Atria
Circulation, February 18, 2003; 107(6): 905 - 910.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Duytschaever, F. Mast, M. Killian, Y. Blaauw, M. Wijffels, and M. Allessie
Methods for Determining the Refractory Period and Excitable Gap During Persistent Atrial Fibrillation in the Goat
Circulation, August 21, 2001; 104(8): 957 - 962.
[Abstract] [Full Text] [PDF]



 
  cardiology careers collections past issues search home